세계의 오토인젝터 시장 : 사용법별, 투여 경로별, 전달 분자 유형별, 작용기전 유형별, 용기 용량별, 최종 사용자별, 표적 적응증별, 주요 지역별

GLOBAL AUTOINJECTORS MARKET (5TH EDITION): OVERVIEW

As per Roots Analysis, the global autoinjectors market is estimated to grow from USD 90.6 billion in the current year to USD 175.9 billion by 2035, at a CAGR of 6.2% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Usability

• Disposable
• Reusable

Route of Administration

• Subcutaneous
• Intravenous
• Intramuscular

Type of Molecule Delivered

• Antibodies
• Peptides
• Proteins
• Small Molecules
• Others

Type of Actuation Mechanism

• Manual
• Automatic

Volume of Container

• Less than 1 mL
• 1-2 mL
• More than 2 mL

End-user

• Ambulatory Surgical Centers
• Home Care
• Hospitals and Clinics

Target Indication

• Anaphylaxis
• Diabetes
• Migraine
• Multiple Sclerosis
• Rheumatoid Arthritis
• Weight Loss
• Others

Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and North Africa
• Latin America

GLOBAL AUTOINJECTORS MARKET (5TH EDITION): GROWTH AND TRENDS

The global rise in chronic diseases, such as diabetes, multiple sclerosis, rheumatoid arthritis and severe allergies, has driven a pressing requirement for a more efficient, innovative and user-friendly drug delivery systems. It is worth highlighting that the impact of these chronic conditions on patients is substantial, as the associated costs and complications can escalate dramatically over a period. As a result, the medical industry has made significant efforts in developing novel drug delivery devices, including autoinjectors.

Autoinjectors are automatic injection devices that are used for the delivery of drugs through the subcutaneous or intramuscular routes. These are primarily spring-driven devices that use prefilled syringes or cartridges as primary containers. By complete or partial automation of the drug delivery process, these devices make the dosing process more convenient. Owing to which, autoinjectors have demonstrated significant potential as the next generation of patient-centric devices, capable of safe and reliable delivery of injectables. Further, the advent of novel biologics is driving the demand for injection of higher viscosities of drugs in larger volumes. Consequently, many device manufacturers, such as BD Medical and SHL, have introduced large volume autoinjectors. Additionally, the new autoinjector devices, which are currently under development, are capable of addressing the specific needs and wants of individual patients. These are designed to enable adjustments in the dosage or features of the device based upon the requirements of the user. In fact, connecting the injectors digitally to various products and platforms is expected to improve adherence and quality of life for the patients. Given these advancements in autoinjectors, the growing need for effective drug delivery systems and disease management can be efficiently addressed in the future.

GLOBAL AUTOINJECTORS MARKET: KEY INSIGHTS

The report delves into the current state of the global autoinjectors market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. Presently, close to 150 autoinjectors are available / being manufactured by various players, globally; the majority of the autoinjector manufacturers are headquartered in North America.

2. Most of the commercially available autoinjectors are suitable for subcutaneous administration; these autoinjectors are integrated with audible and visual indicators and can deliver a myriad of molecules.

3. More than 50% of the deals in the autoinjectors domain were inked in the last three years; further, most of the intercontinental as well as intracontinental partnerships have been signed by players based in Europe.

4. Since 2019, more than 1,100 patents related to autoinjectors have been filed by / granted to various stakeholders to protect the intellectual property generated within this domain.

5. Several scientists, clinicians and industry veterans, affiliated to academic / medical / commercial organizations, are spearheading research related to autoinjectors.

6. Nearly 160 autoinjector combination products (with different drugs) have been approved by regulatory authorities, across the world; further, close to 60% of autoinjector combination product developers are very large players.

7. Around 75% of the commercialized autoinjector combination products are compatible with syringes; notably, majority of these combination products are intended to be used in homecare settings by adults.

8. More than 70 autoinjector combination products intended for the treatment of various indications are currently being evaluated in early and late stages of development; further, most of the developers for these products are publicly listed companies.

9. Around 90% of the early and late-stage combination products are currently in different clinical phases of development; majority of these are being developed for the treatment of chronic conditions (primarily rheumatoid arthritis).

10. The autoinjectors market is anticipated to grow at a steady rate; notably, disposable autoinjectors are likely to capture over 88% market share in 2024 as they eliminate the need for manual loading of medication and have lower risk of contamination.

11. Autoinjectors with automatic actuation mechanism are anticipated to grow at faster pace (~7%) till 2035; further, the autoinjectors intended for delivering drugs targeting rheumatoid arthritis are likely to dominate the current market.

12. The autoinjectors suitable for home care are likely to capture majority share in the market during the forecasted period; Asia-Pacific is anticipated to grow at higher rate in this domain, till 2035.

GLOBAL AUTOINJECTORS MARKET (5TH EDITION): KEY SEGMENTS

Disposable Autoinjectors Occupies the Largest Share of the Global Autoinjectors Market

Based on the usability, the market is segmented into disposable autoinjectors and reusable autoinjectors. At present, disposable autoinjectors segment hold the maximum share of the global autoinjectors market. This trend is likely to remain the same in the forthcoming years.

Autoinjectors for Intravenous Drug Delivery is the Fastest Growing Segment of the Global Autoinjectors Market During the Forecast Period

Based on the route of administration, the market is segmented into subcutaneous, intramuscular and intravenous routes. Currently, autoinjectors used for subcutaneous drug delivery capture the highest proportion of the global autoinjectors market. It is worth highlighting that the global autoinjector market for intravenous autoinjector segment is likely to grow at a relatively higher CAGR.

Proteins Segment Occupy the Largest Share of the Global Autoinjectors Market by Type of Molecule Delivered

Based on the type of molecule delivered, the market is segmented into antibodies, peptides, proteins, small molecules and others. At present, autoinjectors designed for the delivery of proteins hold the maximum share of the global autoinjectors market. This trend is likely to change in the foreseeable future.

By Type of Actuation Mechanism, Autoinjectors with Automatic Actuation Mechanism is the Fastest Growing Segment of the Global Autoinjectors Market During the Forecast Period

Based on the type of actuation mechanism, the market is segmented into manual and automatic actuation mechanism based autoinjectors. At present, autoinjectors equipped with automatic actuation mechanisms capture the highest proportion of the global autoinjectors market. Further, it is worth highlighting that the global autoinjector market for automatic actuation mechanism based autoinjectors is likely to grow at a relatively higher CAGR.

Autoinjectors with Volume Containers of 1-2 mL Account for the Largest Share of the Global Autoinjectors Market

Based on the volume of containers, the market is segmented into autoinjectors with less than 1 ml, 1-2 ml and more than 2 ml storing volumes. Currently, autoinjectors with a drug storing capacity of 1-2 ml of a drug hold the maximum share of the global autoinjectors market. This trend is likely to remain the same in the coming decade.

By End-user, Home Care Segment is Likely to Dominate the Global Autoinjectors Market

Based on the end-user, the market is segmented into home care, hospitals and clinics and ambulatory surgical centers. At present autoinjectors used in the home care segment hold the maximum share of the global autoinjectors market. Additionally, this segment is likely to grow at a faster pace, compared to the other segments.

Autoinjectors Designed for the Treatment of Rheumatoid Arthritis Occupy the Largest Share of the Global Autoinjectors Market

Based on the target indication, the market is segmented into anaphylaxis, diabetes, migraine, multiple sclerosis, rheumatoid arthritis, weight loss and other indications. Whilst rheumatoid arthritis target indication segment is expected to be the primary driver of the overall market, it is worth highlighting that the global autoinjectors market for weight loss segment is likely to grow at a relatively higher CAGR.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa. The majority share is expected to be captured by players based in North America and Europe.

Example Players in the Global Autoinjectors Market

• Amgen
• Antares Pharma
• ChemProtect.SK
• Elcam Medical
• Eli Lilly and Company
• Jiangsu Delfu Medical Device
• Kindeva Drug Delivery
• Merck
• Novartis
• Novo Nordisk
• Oval Medical Technologies
• Owen Mumford
• PreciHealth
• Recipharm
• Sanofi
• SHL Medical
• Teva Pharmaceuticals
• Union Medico
• Ypsomed

GLOBAL AUTOINJECTORS MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global autoinjectors market, focusing on key market segments, including [A] usability, [B] route of administration, [C] type of molecule delivered, [D] type of actuation mechanism, [E] volume of container, [F] end-user, [G] target indication and [H] key geographical regions.
• Autoinjectors Market Landscape: A comprehensive evaluation of autoinjectors, considering various parameters, such as [A] status of development, [B] usability, [C] type of primary drug container, [D] requirement of needle, [E] volume of container, [F] type of dose delivered, [G] route of administration, [H] type of actuation mechanism, [I] type of feedback mechanism, [J] availability of connectivity feature, [K] target indication, [L] type of molecule delivered and [M] end-user. Additionally, a comprehensive evaluation of the companies engaged in manufacturing autoinjectors, based on several relevant parameters, such as [N] year of establishment, [O] company size (in terms of employee count), [P] location of headquarters, [Q] type of company and [R] most active players (in terms of number of autoinjectors manufactured).
• Product Competitiveness Analysis: A comprehensive competitive analysis of autoinjectors, examining factors, such as [A] manufacturer strength and [B] product strength.
• Brand Positioning Analysis: A comprehensive brand positioning assessment framework of the autoinjector manufacturers focusing on the current perceptions of their proprietary brands across various device types. This analysis evaluates autoinjector manufacturers by various parameters, including [A] strength and diversity of product portfolio, [B] routes of administration, [C] type of actuation mechanism, [D] type of feedback mechanism, [E] geographical presence / reach and [F] supplier strength of each player.
• Company Profiles of Autoinjectors Manufacturers: In-depth profiles of key autoinjector manufacturers, focusing on [A] company overviews, [B] financial information (if available), [C] autoinjectors portfolio, [D] manufacturing capabilities and facilities, [E] recent developments and [F] an informed future outlook.
• Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in the global autoinjectors market, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] type of partner, [D] most active players (in terms of the number of partnerships signed) and [E] geographical distribution of partnership activity.
• Patent Analysis: An in-depth analysis of patents filed / granted till date in the autoinjectors domain, based on various relevant parameters, such as [A] type of patent, [B] patent publication year, [C] patent application year, [D] patent jurisdiction, [E] CPC symbols, [F] type of applicant, [G] most active players, [H] patent benchmarking and [I] patent valuation analysis.
• Commercialized Autoinjector Combination Product Market Landscape: A comprehensive evaluation of commercialized autoinjector combination products, considering various parameters, such as [A] approval year, [B] usability, [C] type of primary drug container, [D] requirement of needle, [E] volume of container, [F] injection time, [G] type of dose delivered, [H] route of administration, [I] type of actuation mechanism, [J] type of feedback mechanism, [K] availability of connectivity feature, [L] target indication, [M] severity of indication, [N] type of molecule delivered, [O] end-user and [P] target population. Additionally, a comprehensive evaluation of the companies engaged in manufacturing commercialized autoinjector combination product, based on several relevant parameters, such as [Q] year of establishment, [R] company size (in terms of employee count), [S] location of headquarters, [T] type of company and [U] most active players (in terms of number of commercialized autoinjector combination products developed).
• Early and Late Stage Autoinjectors Combination Product Market Landscape: A comprehensive evaluation of early and late stage autoinjector combination products, considering various parameters, such as [A] stage of development, [B] route of administration, [C] dose strength, [D] target indication, [E] severity of indication, [F] type of molecule delivered, [G] end-user, [H] target population and [I] gender of target population. Additionally, a comprehensive evaluation of the companies engaged in manufacturing early and late stage autoinjector combination products, based on several relevant parameters, such as [J] year of establishment, [K] company size (in terms of employee count), [L] location of headquarters and [M] type of company.
• Short Company Profiles of Autoinjector Combination Product Manufacturers: Short profiles of key autoinjector combination product manufacturers, focusing on [A] company overviews and [B] autoinjector product portfolio.
• Key Opinion Leaders (KOLs]: An in-depth analysis that emphasizes the key opinion leaders in this domain, considering various parameters, such as [A] role of KOL, [B] type of sponsor organization, [C] affiliated organization, [D] target indication, [E] location of clinical trials and [F] most prominent KOLs.
• Case Study 1: A general discussion on most commonly targeted indications, providing information on approved autoinjector combination products.
• Case Study 2: A general discussion on the role of medical device CMOs in the manufacturing and assembly of drug-delivery devices, including autoinjectors, based on several relevant parameters, such as [A] scale of operation and [B] types of services provided for production of devices.
• Case Study 3: A detailed assessment of prefilled syringes that are either commercialized or under development based on several relevant parameters, such as [A] type of barrel fabrication material, [B] number of barrel chambers, [C] type of needle system. In addition, the chapter provides a detailed analysis of prefilled syringe manufacturers, based on various parameters, such as [D] year of establishment, [E] company size (in terms of employee count) and [F] location of headquarters.
• SWOT Analysis: An analysis of industry affiliated trends, opportunities and challenges, which are likely to impact the evolution of autoinjectors market; it includes a Harvey ball analysis, assessing the relative impact of each SWOT parameter on industry dynamics.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Market Share Insights
• 1.3. Key Marget Insights
• 1.4. Report Coverage
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
• 2.3. Project Methodology
• 2.4. Forecast Methodology
• 2.5. Robust Quality Control
• 2.6. Key Market Segmentation
• 2.7. Key Considerations
  • 2.7.1. Demographics
  • 2.7.2. Economic Factors
  • 2.7.3. Government Regulations
  • 2.7.4. Supply Chain
  • 2.7.5. COVID Impact
  • 2.7.6. Market Access
  • 2.7.7. Healthcare Policies
  • 2.7.8. Industry Consolidation

3.ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

• 3.1. Chapter Overview
• 3.2. Market Dynamics
  • 3.2.1. Time Period
    • 3.2.1.1. Historical Trends
    • 3.2.1.2. Current and Future Estimates
  • 3.2.2. Currency Coverage and Foreign Exchange Rate
    • 3.2.2.1. Major Currencies Affecting the Market
    • 3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
    • 3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
    • 3.2.2.4. Strategies for Mitigating Foreign Exchange Risk
  • 3.2.3. Trade Policies
    • 3.2.3.1. Impact of Trade Barriers on the Market
    • 3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers
  • 3.2.4. Recession
    • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
    • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
  • 3.2.5. Inflation
    • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

• 5.1. Chapter Overview
• 5.2. Types of Drug Delivery Systems
• 5.3. Drawbacks of Conventional Parenteral Delivery Systems
• 5.4. Emerging Trend of Self-Administration
  • 5.4.1. Rising Burden of Chronic Diseases
  • 5.4.2. Healthcare Cost Savings
  • 5.4.3. Need for Immediate Treatment in Emergency Situations
  • 5.4.4. Growth of Injectable Biologics Market
  • 5.4.5. Addressing Key User Safety Requirements
• 5.5. Types of Self-Administration Devices
  • 5.5.1. Prefilled Syringes
  • 5.5.2. Pen-Injectors
  • 5.5.3. Needle-Free Injectors
  • 5.5.4. Large Volume Wearable Injectors
  • 5.5.5. Autoinjectors
• 5.6. Overview of Autoinjectors
  • 5.6.1. Components of Autoinjectors
  • 5.6.2. Classification of Autoinjectors
    • 5.6.2.1. Classification Based on Mechanism of Action
    • 5.6.2.2. Classification Based on Usability
    • 5.6.2.3. Classification Based on Type of Dose Delivered
  • 5.6.3. Manufacturing / Packaging of Autoinjectors
  • 5.6.4. Benefits of Autoinjectors
• 5.7. Regulatory Considerations
  • 5.7.1. Medical Devices
  • 5.7.2. Drug Device Combination Products
• 5.8. Future Perspectives

6. PRIMARY DRUG CONTAINERS USED IN AUTOINJECTORS

• 6.1. Chapter Overview
• 6.2. Types of Packaging
• 6.3. Primary Drug Containers
  • 6.3.1. Role of Primary Drug Containers
  • 6.3.2. Cartridges
    • 6.3.2.1. Components of Cartridges
    • 6.3.2.2. Types of Cartridges
      • 6.3.2.2.1. Single Chamber Cartridge
      • 6.3.2.2.2. Dual Chamber Cartridge
    • 6.3.2.3. Commercially Available Cartridges
  • 6.3.3. Syringes
    • 6.3.3.1. Components of Syringes
    • 6.3.3.2. Classification of Syringes
      • 6.3.3.2.1. Classification Based on Barrel Fabrication Material
      • 6.3.3.2.2. Classification Based on Number of Chambers in the Barrel
      • 6.3.3.2.3. Classification Based on Type of Needle
  • 6.3.4. Vials
    • 6.3.4.1. Components of Vials
    • 6.3.4.2. Commercially Available Vials
• 6.4. Comparison of Different Fabrication Materials

7. AUTOINJECTORS: MARKET OVERVIEW

• 7.1. Chapter Overview
• 7.2. Autoinjectors: Overall Market Landscape
  • 7.2.1. Analysis by Stage of Development
  • 7.2.2. Analysis by Usability
  • 7.2.3. Analysis by Type of Primary Drug Container
  • 7.2.4. Analysis by Requirement of Needle
  • 7.2.5. Analysis by Volume of Container
  • 7.2.6. Analysis by Type of Dose Delivered
  • 7.2.7. Analysis by Route of Administration
  • 7.2.8. Analysis by Type of Actuation Mechanism
  • 7.2.9. Analysis by Type of Feedback Mechanism
  • 7.2.10. Analysis by Availability of Connectivity Feature
  • 7.2.11. Analysis by Target Indication
  • 7.2.12. Analysis by Type of Molecule Delivered
  • 7.2.13. Analysis by End-user
• 7.3. Autoinjector Manufacturers: Overall Market Landscape
  • 7.3.1. Analysis by Year of Establishment
  • 7.3.2. Analysis by Company Size
  • 7.3.3. Analysis by Location of Headquarters
  • 7.3.4. Analysis by Company Size and Location of Headquarters
  • 7.3.5. Analysis by Type of Company
  • 7.3.6. Most Active Players: Analysis by Number of Autoinjectors

8. PRODUCT COMPETITIVENESS ANALYSIS

• 8.1. Chapter Overview
• 8.2. Assumptions and Key Parameters
• 8.3. Methodology
• 8.4. Autoinjectors: Product Competitiveness Analysis
  • 8.4.1. Disposable Autoinjectors
  • 8.4.2. Reusable Autoinjectors

9. BRAND POSITIONING ANALYSIS

• 9.1. Chapter Overview
• 9.2. Assumptions and Key Parameters
• 9.3. Methodology
• 9.4. Autoinjector Manufacturers: Brand Positioning Framework
  • 9.4.1. Brand Positioning Framework: Owen Mumford
  • 9.4.2. Brand Positioning Framework: Ypsomed
  • 9.4.3. Brand Positioning Framework: Elcam Medical
  • 9.4.4. Brand Positioning Framework: SHL Medical
  • 9.4.5. Brand Positioning Framework: Union Medico
  • 9.4.6. Brand Positioning Framework: Antares Pharma
  • 9.4.7. Brand Positioning Framework: PreciHealth
  • 9.4.8. Brand Positioning Framework: Jiangsu Delfu Medical Device
  • 9.4.9. Brand Positioning Framework: Oval Medical Technologies
  • 9.4.10. Brand Positioning Framework: Recipharm

10. AUTOINJECTOR MANUFACTURERS: DETAILED COMPANY PROFILES

• 10.1. Chapter Overview
• 10.2. Antares Pharma
  • 10.2.1. Company Overview
  • 10.2.2. Financial Information
  • 10.2.3. Autoinjectors Portfolio
  • 10.2.4 Recent Developments and Future Outlook
• 10.3. Elcam Medical
  • 10.3.1. Company Overview
  • 10.3.2. Autoinjectors Portfolio
  • 10.3.3. Recent Developments and Future Outlook
• 10.4. Jiangsu Delfu Medical Device
  • 10.4.1. Company Overview
  • 10.4.2. Autoinjectors Portfolio
  • 10.4.3. Recent Developments and Future Outlook
• 10.5. Oval Medical Technologies
  • 10.5.1. Company Overview
  • 10.5.2. Autoinjectors Portfolio
  • 10.5.3. Recent Developments and Future Outlook
• 10.6. Owen Mumford
  • 10.6.1. Company Overview
  • 10.6.2. Autoinjectors Portfolio
  • 10.6.3. Recent Developments and Future Outlook
• 10.7. PreciHealth
  • 10.7.1. Company Overview
  • 10.7.2. Autoinjectors Portfolio
  • 10.7.3. Recent Developments and Future Outlook
• 10.8. Recipharm
  • 10.8.1. Company Overview
  • 10.8.2. Financial Information
  • 10.8.3. Autoinjectors Portfolio
  • 10.8.4. Recent Developments and Future Outlook
• 10.9. SHL Medical
  • 10.9.1. Company Overview
  • 10.9.2. Autoinjectors Portfolio
  • 10.9.3. Recent Developments and Future Outlook
• 10.10. Union Medico
  • 10.10.1. Company Overview
  • 10.10.2. Autoinjectors Portfolio
  • 10.10.3. Recent Developments and Future Outlook
• 10.11. Ypsomed
  • 10.11.1. Company Overview
  • 10.11.2. Financial Information
  • 10.11.3. Autoinjectors Portfolio
  • 10.11.4. Recent Developments and Future Outlook

11. PARTNERSHIPS AND COLLABORATIONS

• 11.1. Chapter Overview
• 11.2. Partnership Models
• 11.3. Autoinjectors: Partnerships and Collaborations
  • 11.3.1. Analysis by Year of Partnership
  • 11.3.2. Analysis by Type of Partnership
  • 11.3.3. Analysis by Year and Type of Partnership
  • 11.3.4. Analysis by Type of Product
  • 11.3.5. Analysis by Type of Partner
  • 11.3.6. Most Active Players: Analysis by Number of Partnerships
  • 11.3.7. Analysis by Geography
    • 11.3.7.1. Intracontinental and Intercontinental Deals
    • 11.3.7.2. International and Local Deals

12. PATENT ANALYSIS

• 12.1. Chapter Overview
• 12.2. Scope and Methodology
• 12.3. Autoinjectors: Patent Analysis
  • 12.3.1. Analysis by Patent Publication Year
  • 12.3.2. Analysis by Type of Patent and Patent Publication Year
  • 12.3.3. Analysis by Patent Application Year
  • 12.3.4. Analysis by Patent Jurisdiction
  • 12.3.5. Analysis by CPC Symbols
  • 12.3.6. Analysis by Type of Applicant
  • 12.3.7. Leading Industry Players: Analysis by Number of Patents
  • 12.3.8. Leading Individual Assignees: Analysis by Number of Patents
• 12.4. Patent Benchmarking Analysis
  • 12.4.1. Analysis By Patent Characteristics
• 12.5. Patent Valuation
• 12.6. Leading Patents by Number of Citations

13. DRUG DEVICE COMBINATIONS: COMMERCIALIZED AUTOINJECTORS

• 13.1. Chapter Overview
• 13.2. Drug Device Combinations: Commercialized Autoinjectors
  • 13.2.1. Analysis by Approval Year
  • 13.2.2. Analysis by Usability
  • 13.2.3. Analysis by Type of Primary Drug Container
  • 13.2.4. Analysis by Requirement of Needle
  • 13.2.5. Analysis by Volume of Container
  • 13.2.6. Analysis by Injection Time
  • 13.2.7. Analysis by Type of Dose Delivered
  • 13.2.8. Analysis by Route of Administration
  • 13.2.9. Analysis by Type of Actuation Mechanism
  • 13.2.10. Analysis by Type of Feedback Mechanism
  • 13.2.11. Analysis by Availability of Connectivity Feature
  • 13.2.12. Analysis by Target Indication
  • 13.2.13. Analysis by Severity of Indication
  • 13.2.14. Analysis by Type of Molecule Delivered
  • 13.2.15. Analysis by End-user
  • 13.2.16. Analysis by Target Population
• 13.3. Drug Device Combinations: Commercialized Autoinjector Developers
  • 13.3.1. Analysis by Year of Establishment
  • 13.3.2. Analysis by Company Size
  • 13.3.3. Analysis by Location of Headquarters
  • 13.3.4. Analysis by Company Size and Location of Headquarters
  • 13.3.5. Analysis by Type of Company
  • 13.3.6. Most Active Players: Analysis by Number of Commercialized Autoinjector Combination Products

14. DRUG DEVICE COMBINATIONS: EARLY AND LATE STAGE AUTOINJECTORS

• 14.1. Chapter Overview
• 14.2. Drug Device Combinations: Early and Late Stage Autoinjectors
  • 14.2.1. Analysis by Stage of Development
  • 14.2.2. Analysis by Route of Administration
  • 14.2.3. Analysis by Dose Strength
  • 14.2.4. Analysis by Target Indication
  • 14.2.5. Analysis by Severity of Indication
  • 14.2.6. Analysis by Type of Molecule Delivered
  • 14.2.7. Analysis by End-user
  • 14.2.8. Analysis by Target Population
  • 14.2.9. Analysis by Gender of Target Population
• 14.3. Drug Device Combinations: Early and Late Stage Autoinjector Developers Landscape
  • 14.3.1. Analysis by Year of Establishment
  • 14.3.2. Analysis by Company Size
  • 14.3.3. Analysis by Location of Headquarters
  • 14.3.4. Analysis by Company Size and Location of Headquarters
  • 14.3.5. Analysis by Type of Company

15 SHORT COMPANY PROFILES: AUTOINJECTOR COMBINATION PRODUCT DEVELOPERS

• 15.1. Chapter Overview
• 15.2. Amgen
  • 15.2.1. Company Overview
  • 15.2.2. Autoinjector Combination Product Portfolio
• 15.3. ChemProtect.SK
  • 15.3.1. Company Overview
  • 15.3.2. Autoinjector Combination Product Portfolio
• 15.4. Eli Lilly and Company
  • 15.4.1. Company Overview
  • 15.4.2. Autoinjector Combination Product Portfolio
• 15.5. Kindeva Drug Delivery
  • 15.5.1. Company Overview
  • 15.5.2. Autoinjector Combination Product Portfolio
• 15.6. Merck
  • 15.6.1. Company Overview
  • 15.6.2. Autoinjector Combination Product Portfolio
• 15.7. Novartis
  • 15.7.1. Company Overview
  • 15.7.2. Autoinjector Combination Product Portfolio
• 15.8. Novo Nordisk
  • 15.8.1. Company Overview
  • 15.8.2. Autoinjector Combination Product Portfolio
• 15.9. Sanofi
  • 15.9.1. Company Overview
  • 15.9.2. Autoinjector Combination Product Portfolio
• 15.10. Teva Pharmaceutical Industries
  • 15.10.1. Company Overview
  • 15.10.2. Autoinjector Combination Product Portfolio

16. KEY OPINION LEADER ANALYSIS

• 16.1. Chapter Overview
• 16.2. Assumption and Key Parameters
• 16.3. Methodology
• 16.4. Autoinjectors: Key Opinion Leaders
  • 16.4.1. Analysis by Role of KOL
  • 16.4.2. Analysis by Type of Sponsor Organization
  • 16.4.3. Analysis by Affiliated Organization
  • 16.4.4. Analysis by Target Indication
  • 16.4.5. Analysis by Location of Clinical Trials
  • 16.4.6 Most Prominent KOLs: Analysis by Activeness, Expertise and Strength of KOL
  • 16.4.7. Most Prominent KOLs: Analysis by Roots Analysis Score

17. CASE STUDY: KEY THERAPEUTIC INDICATIONS

• 17.1. Chapter Overview
• 17.2. Anaphylaxis
  • 17.2.1. Overview and Epidemiology
  • 17.2.2. Treatment for Anaphylaxis
  • 17.2.3. Autoinjectors for Anaphylaxis
• 17.3. Multiple Sclerosis
  • 17.3.1. Overview and Epidemiology
  • 17.3.2. Treatment for Multiple Sclerosis
  • 17.3.3. Autoinjectors for Multiple Sclerosis
• 17.4. Migraine
  • 17.4.1. Overview and Epidemiology
  • 17.4.2. Treatment for Migraine
  • 17.4.3. Autoinjectors for Migraine
• 17.5. Rheumatoid Arthritis
  • 17.5.1. Overview and Epidemiology
  • 17.5.2. Treatment for Rheumatoid Arthritis
  • 17.5.3. Autoinjectors for Rheumatoid Arthritis

18. CASE STUDY: MEDICAL DEVICE CONTRACT SERVICE PROVIDERS

• 18.1. Chapter Overview
• 18.2. Challenges Associated with Medical Device Manufacturing
• 18.3. Role of CMOs in Medical Device Manufacturing
• 18.4. Services Offered by Medical Device CMOs
• 18.5. Advantages Offered by Medical Device CMOs
• 18.6. Risks Associated with Outsourcing to CMOs
• 18.7. Drug Delivery Device Service Providers
  • 18.7.1. Analysis by Year of Establishment
  • 18.7.2. Analysis by Company Size
  • 18.7.3. Analysis by Location of Headquarters
  • 18.7.4. Analysis by Type of Services
• 18.8. Concluding Remarks

19. CASE STUDY: PREFILLED SYRINGES

• 19.1. Chapter Overview
• 19.2. Prefilled Syringes: Market Landscape
  • 19.2.1. Analysis by Type of Barrel Fabrication Material
  • 19.2.2. Analysis by Number of Barrel Chambers
  • 19.2.3. Analysis by Type of Needle System
• 19.3. Prefilled Syringes Manufacturers: Overall Market Landscape
  • 19.3.1. Analysis by Year of Establishment
  • 19.3.2. Analysis by Company Size
  • 19.3.3. Analysis by Location of Headquarters
• 19.4. Future Perspectives

20. SWOT ANALYSIS

• 20.1. Chapter Overview
• 20.2. Strengths
  • 20.2.1. Ease of Drug Delivery
  • 20.2.2. Ability to Minimize / Eliminate Medication Errors
  • 20.2.3. Enhanced Safety Features
  • 20.2.4. Economic Advantages
  • 20.2.5. Drug Life Cycle Management
• 20.3. Weaknesses
  • 20.3.1. Manufacturing Complexities
  • 20.3.2. Customized Design for Different Formulations
  • 20.3.3. Use Errors
  • 20.3.4. Stringent Regulatory Guidelines
• 20.4. Opportunities
  • 20.4.1. Rich and Growing Pipeline of Biologics and Biosimilars
  • 20.4.2. Growing Preference for Self-Injection Devices
  • 20.4.3. Integration of Advanced Technologies
  • 20.4.4. Rising Popularity across the Globe
• 20.5. Threats
  • 20.5.1. Material Compatibility Issues
  • 20.5.2. Availability of Alternative Drug Delivery Devices
  • 20.5.3. Concern Related to Numerous Product Recalls in Past
• 20.6. Concluding Remarks

21. GLOBAL AUTOINJECTORS MARKET

• 21.1. Chapter Overview
• 21.2. Key Assumptions and Methodology
• 21.3. Global Autoinjectors Market, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 21.3.1. Scenario Analysis
    • 21.3.1.1. Conservative Scenario
    • 21.3.1.2 Optimistic Scenario
• 21.4. Key Market Segmentations

22. AUTOINJECTORS MARKET, FOR RHEUMATOID ARTHRITIS

• 22.1. Chapter Overview
• 22.2. Key Assumptions and Methodology
• 22.3. Autoinjectors Market for Rheumatoid Arthritis: Distribution by Usability
  • 22.3.1. Disposable Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 22.3.2. Reusable Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 22.4. Autoinjectors Market for Rheumatoid Arthritis: Distribution by Route of Administration
  • 22.4.1. Subcutaneous Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 22.4.2. Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 22.4.3. Intravenous Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 22.5. Autoinjectors Market for Rheumatoid Arthritis: Distribution by Type of Molecule Delivered
  • 22.5.1. Protein-based Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 22.5.2. Antibody-based Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 22.5.3. Small Molecule-based Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 22.6. Leading Player

23. AUTOINJECTORS MARKET, FOR MULTIPLE SCLEROSIS

• 23.1. Chapter Overview
• 23.2. Key Assumptions and Methodology
• 23.3. Autoinjectors Market for Multiple Sclerosis: Distribution by Usability
  • 23.3.1. Disposable Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 23.3.2. Reusable Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 23.4. Autoinjectors Market for Multiple Sclerosis: Distribution by Route of Administration
  • 23.4.1. Subcutaneous Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 23.4.2. Intramuscular Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 23.5. Autoinjectors Market for Multiple Sclerosis: Distribution by Type of Molecule Delivered
  • 23.5.1. Protein-based Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 23.5.2. Peptide-based Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 23.5.3. Antibody-based Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 23.6. Leading Player

24. AUTOINJECTORS MARKET, FOR DIABETES

• 24.1. Chapter Overview
• 24.2. Key Assumptions and Methodology
• 24.3. Autoinjectors Market for Diabetes: Distribution by Usability
  • 24.3.1. Disposable Autoinjectors Market for Diabetes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 24.3.2. Reusable Autoinjectors Market for Diabetes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 24.4. Autoinjectors Market for Diabetes: Distribution by Route of Administration
  • 24.4.1. Subcutaneous Autoinjectors Market for Diabetes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 24.5. Autoinjectors Market for Diabetes: Distribution by Type of Molecule Delivered
  • 24.5.1. Protein-based Autoinjectors Market for Diabetes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 24.5.2. Antibody-based Autoinjectors Market for Diabetes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 24.6. Leading Player

25. AUTOINJECTORS MARKET, FOR WEIGHT LOSS

• 25.1. Chapter Overview
• 25.2. Key Assumptions and Methodology
• 25.3. Autoinjectors Market for Weight Loss: Distribution by Usability
  • 25.3.1. Disposable Autoinjectors Market for Weight Loss, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 25.4. Autoinjectors Market for Weight Loss: Distribution by Route of Administration
  • 25.4.1. Subcutaneous Autoinjectors Market for Weight Loss, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 25.5. Autoinjectors Market for Weight Loss: Distribution by Type of Molecule Delivered
  • 25.5.1. Peptide-based Autoinjectors Market for Weight Loss, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 25.5.2. Small Molecule-based Autoinjectors Market for Weight Loss, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 25.6. Leading Player

26. AUTOINJECTORS MARKET, FOR ANAPHYLAXIS

• 26.1. Chapter Overview
• 26.2. Key Assumptions and Methodology
• 26.3. Autoinjectors Market for Anaphylaxis: Distribution by Usability
  • 26.3.1. Disposable Autoinjectors Market for Anaphylaxis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 26.4. Autoinjectors Market for Anaphylaxis: Distribution by Route of Administration
  • 26.4.1. Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 26.4.2. Intramuscular Autoinjectors Market for Anaphylaxis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 26.5. Autoinjectors Market for Anaphylaxis: Distribution by Type of Molecule Delivered
  • 26.5.1. Small Molecule-based Autoinjectors Market for Anaphylaxis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 26.6. Leading Player

27. AUTOINJECTORS MARKET, FOR MIGRAINE

• 27.1. Chapter Overview
• 27.2. Key Assumptions and Methodology
• 27.3. Autoinjectors Market for Migraine: Distribution by Usability
  • 27.3.1. Disposable Autoinjectors Market for Migraine, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 27.4. Autoinjectors Market for Migraine: Distribution by Route of Administration
  • 27.4.1. Subcutaneous Autoinjectors Market for Migraine, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 27.5. Autoinjectors Market for Migraine: Distribution by Type of Molecule Delivered
  • 27.5.1. Antibody-based Autoinjectors Market for Migraine, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 27.5.2. Protein-based Autoinjectors Market for Migraine, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 27.5.3. Small Molecule-based Autoinjectors Market for Migraine, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 27.6. Leading Player

28. AUTOINJECTORS MARKET, FOR OTHER INDICATIONS

• 28.1. Chapter Overview
• 28.2. Key Assumptions and Methodology
• 28.3. Autoinjectors Market for Other Indications: Distribution by Usability
  • 28.3.1. Disposable Autoinjectors Market for Other Indications, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 28.3.2. Reusable Autoinjectors Market for Other Indications, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 28.4. Autoinjectors Market for Other Indications: Distribution by Route of Administration
  • 28.4.1. Subcutaneous Autoinjectors Market for Other Indications,

Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)

• 28.4.2. Subcutaneous / Intramuscular Autoinjectors Market for Other Indications, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 28.4.3. Subcutaneous / Intravenous Autoinjectors Market for Other Indications, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 28.5. Autoinjectors Market for Other Indications: Distribution by Type of Molecule Delivered
  • 28.5.1. Antibody-based Autoinjectors Market for Other Indications, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 28.5.2. Protein-based Autoinjectors Market for Other Indications, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 28.5.3. Small Molecule-based Autoinjectors Market for Other Indications, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 28.5.4. Other Molecule-based Autoinjectors Market for Other Indications, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 28.6. Leading Player

29. AUTOINJECTORS MARKET, BY USABILITY

• 29.1. Chapter Overview
• 29.2. Key Assumptions and Methodology
• 29.3. Autoinjectors Market: Distribution by Usability
  • 29.3.1. Disposable Autoinjectors Market: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 29.3.2. Reusable Autoinjectors Market: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 29.4. Data Triangulation and Validation

30. AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION

• 30.1. Chapter Overview
• 30.2. Key Assumptions and Methodology
• 30.3. Autoinjectors Market: Distribution by Route of Administration
  • 30.3.1. Autoinjectors Market for Subcutaneous Administration: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 30.3.2. Autoinjectors Market for Subcutaneous / Intramuscular Administration: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 30.3.3. Autoinjectors Market for Subcutaneous / Intravenous Administration: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 30.3.4. Autoinjectors Market for Intramuscular Administration: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 30.3.5. Autoinjectors Market for Intravenous Administration: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 30.4. Data Triangulation and Validation

31. AUTOINJECTORS MARKET, BY TYPE OF MOLECULE DELIVERED

• 31.1. Chapter Overview
• 31.2. Key Assumptions and Methodology
• 31.3. Autoinjectors Market: Distribution by Type of Molecule Delivered
  • 31.3.1. Autoinjectors Market for Proteins: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 31.3.2. Autoinjectors Market for Antibodies: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 31.3.3. Autoinjectors Market for Small Molecules: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 31.3.4. Autoinjectors Market for Peptides: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 31.3.5. Autoinjectors Market for Other Molecules: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 31.4. Data Triangulation and Validation

32. AUTOINJECTORS MARKET, BY TYPE OF ACTUTATION MECHANISM

• 32.1. Chapter Overview
• 32.2. Key Assumptions and Methodology
• 32.3. Autoinjectors Market: Distribution by Type of Actuation Mechanism
  • 32.3.1. Autoinjectors Market for Manual Actuation: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 32.3.2. Autoinjectors Market for Automatic Actuation: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 32.4. Data Triangulation and Validation

33. AUTOINJECTORS MARKET, BY VOLUME OF CONTAINER

• 33.1. Chapter Overview
• 33.2. Key Assumptions and Methodology
• 33.3. Autoinjectors Market: Distribution by Volume of Container
  • 33.3.1. Autoinjectors Market for Containers with Less than 1 mL Volume: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 33.3.2. Autoinjectors Market for Containers with 1- 2 mL Volume: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 33.3.3. Autoinjectors Market for Containers with More than 2 mL Volume: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 33.4. Data Triangulation and Validation

34. AUTOINJECTORS, BY END-USER

• 34.1. Chapter Overview
• 34.2. Key Assumptions and Methodology
• 34.3. Autoinjectors Market: Distribution by End-user
  • 34.3.1. Autoinjectors Market for Home Care: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 34.3.2. Autoinjectors Market for Hospitals and Clinics: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 34.3.3. Autoinjectors Market for Ambulatory Surgical Centers: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 34.4. Data Triangulation and Validation

35. AUTOINJECTORS MARKET, BY TARGET INDICATION

• 35.1. Chapter Overview
• 35.2. Key Assumptions and Methodology
• 35.3. Autoinjectors Market: Distribution by Target Indication
  • 35.3.1. Autoinjectors Market for Rheumatoid Arthritis: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 35.3.2. Autoinjectors Market for Multiple Sclerosis: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 35.3.3 Autoinjectors Market for Diabetes: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) Data Triangulation
  • 35.3.4. Autoinjectors Market for Anaphylaxis: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 35.3.5. Autoinjectors Market for Weight Loss: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 35.3.6. Autoinjectors Market for Migraine: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 35.3.7. Autoinjectors Market for Other Indications: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 35.4. Data Triangulation and Validation

36. AUTOINJECTORS, BY KEY GEOGRAPHICAL REGIONS

• 36.1. Chapter Overview
• 36.2. Key Assumptions and Methodology
• 36.3. Autoinjectors Market: Distribution by Key Geographical Regions
  • 36.3.1. Autoinjectors Market in North America: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 36.3.2. Autoinjectors Market in Europe: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 36.3.3. Autoinjectors Market in Asia-Pacific: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 36.3.4. Autoinjectors Market in Middle East and North Africa: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 36.3.4. Autoinjectors Market in Latin America: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
• 36.4. Data Triangulation and Validation

37. CONCLUDING REMARKS

38. EXECUTIVE INSIGHTS

• 38.1. Chapter Overview
• 38.2. Aktiv Pharma
  • 38.2.1. Company Snapshot
  • 38.2.2. Interview Transcript
• 38.3. Rx Bandz
  • 38.3.1. Company Snapshot
  • 38.3.2. Interview Transcript
• 38.4. Kindeva Drug Delivery
  • 38.4.1. Company Snapshot
  • 38.4.2. Interview Transcript
• 38.5. DALI Medical Devices
  • 38.5.1. Company Snapshot
  • 38.5.2. Interview Transcript:
• 38.6. Elcam Medical
  • 38.6.1. Company Snapshot
  • 38.6.2. Interview Transcript
• 38.7. Pharma Consult
  • 38.7.1. Company Snapshot
  • 38.7.2. Interview Transcript
• 38.8. IDEO
  • 38.8.1. Company Snapshot
  • 38.8.2. Interview Transcript
• 38.9. Bill & Melinda Gates Foundation
  • 38.9.1. Company Snapshot
  • 38.9.2. Interview Transcript
• 38.10. Oval Medical Technologies
  • 38.10.1. Company Snapshot
  • 38.10.2. Interview Transcript
• 38.11. Anonymous
• 38.12. Anonymous
• 38.13. Anonymous
• 38.14. Anonymous

39. APPENDIX 1: TABULATED DATA

40. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION